Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.44 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL16975005 | 0.87 | ALDH1A1 (0.53) | ALDH1A1LMNAKMT2AMAPTPOLB | |
| Propionic Acid SCHEMBL28700286 | 0.86 | EHMT2 (0.63) | ALDH1A1LMNAKMT2AMAPTPOLB | |
| Carbamic Acid SCHEMBL16975014 | 0.84 | ALDH1A1 (0.50) | ALDH1A1LMNAKMT2AMAPTPOLB | |
| SCHEMBL23804874 | 0.82 | LMNA (0.43) | ALDH1A1LMNAKMT2AMAPTPOLB | |
| Methacrylic Acid SCHEMBL421102 | 0.81 | ALDH1A1 (0.45) | ALDH1A1LMNAKMT2AMAPTPOLB | |
| SCHEMBL35924 | 0.81 | — | — | |
| SCHEMBL15255079 | 0.81 | ALDH1A1 (0.42) | ALDH1A1LMNAKMT2AMAPTPOLB | |
| Ethylamine SCHEMBL18229942 | 0.80 | EHMT2 (0.48) | ALDH1A1LMNAKMT2ASMN1; SMN2RAB9A | |
| Propionic Acid SCHEMBL11825315 | 0.80 | ALDH1A1 (0.55) | ALDH1A1LMNAKMT2AMAPTPOLB | |
| Ethylene Glycol SCHEMBL5087076 | 0.80 | EHMT2 (0.52) | ALDH1A1LMNAKMT2AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734238-B1 | SUGAR ALCOHOL-BASED CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2020-02-19 | — | — | EP | disclosed |
| US-9907854-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-9511150-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2016-12-06 | — | — | US | disclosed |
| US-8907079-B2 | Crosslinking reagents, macromolecules, therapeutic conjugates, and synthetic methods thereof | CELLMOSAIC INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140206903-A1 | NOVELCROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC CONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2014-07-24 | — | — | US | disclosed |
| EP-2734238-A2 | SUGAR ALCOHOL-BASED CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | Cellmosaic, LLC (US) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013012961-A2 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC CONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC, LLC (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-0946744-B1 | NOVEL POLYMERIC COMPLEXES FOR THE TRANSFECTION OF NUCLEIC ACIDS, WITH RESIDUES CAUSING THE DESTABILISATION OF CELL MEMBRANES | IDM IMMUNO DESIGNED MOLECULES (FR) | 2004-08-18 | — | — | EP | disclosed |
| EP-0946744-A1 | NOVEL POLYMERIC COMPLEXES FOR THE TRANSFECTION OF NUCLEIC ACIDS, WITH RESIDUES CAUSING THE DESTABILISATION OF CELL MEMBRANES | I.D.M. IMMUNO-DESIGNED MOLECULES (FR) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998022610-A1 | NOVEL POLYMERIC COMPLEXES FOR THE TRANSFECTION OF NUCLEIC ACIDS, WITH RESIDUES CAUSING THE DESTABILISATION OF CELL MEMBRANES | I.D.M. IMMUNO-DESIGNED MOLECULES (FR) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CD44, ADH1C, EPCAM | ALDH1A1 161/4885LMNA 4262/4885KMT2A 1086/4885 |
| US-20140206903-A1 | NOVELCROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC CONJUGATES, AND SYNTHETIC METHODS THEREOF | CD44, ADH1C, EPCAM | ALDH1A1 106/4885LMNA 4454/4885KMT2A 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.